Stem Cells in the Treatment of Disease

Blau, Helen M.; Daley, George Q.

doi:10.1056/nejmra1716145

Cited by 171 publications

(140 citation statements)

References 88 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…Compared with other stem cell types in cord blood, MSCs are more attractive to researchers, as it is non‐immunogenic and can be expanded rapidly ex vivo . With these properties, allogeneic transplantation of MSCs are used for treatment of diseases in adult and neonates . ACBMNC, as a convenient source of MSC, has never been studied in prevention or treatment of BPD in preterm.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Autologous cord blood cell infusion in preterm neonates safely reduces respiratory support duration and potentially preterm complications

Ren

Zhang

et al. 2019

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Preterm birth and its complications are the leading cause of neonatal death. The main underlying pathological mechanisms for preterm complications are disruption of the normal maturation processes within the target tissues, interrupted by premature birth.Cord blood, as a new and convenient source of stem cells, may provide new, promising options for preventing preterm complications. This prospective, nonrandomized placebo controlled study aimed at investigating the effect of autologous cord blood mononuclear cells (ACBMNC) for preventing preterm associated complications. Preterm infants less than 35 weeks gestational age were assigned to receive ACBMNC (5 × 10 7 cells/kg) intravenous or normal saline within 8 hours after birth. Preterm complication rates were compared between two groups to demonstrate the effect of ACBMNC infusion in reducing preterm complications. Fifteen preterm infants received ACBMNC infusion, and 16 infants were assigned to the control group. There were no significant differences when comparing mortality and preterm complication rates before discharge. However, ACBMNC infusion demonstrated significant decreases in duration of mechanical ventilation (3.2 days vs 6.41 days, P = .028) and oxygen therapy (5.33 days vs 11.31 days, P = .047). ACBMNC infusion was effective in reducing respiratory support duration in very preterm infants. Due to the limited number of patients enrolled, powered randomized controlled trials are needed to better define its efficacy. K E Y W O R D Sautologous cord blood cells, effect, preterm complication, prevention

show abstract

Section: Discussionmentioning

confidence: 99%

“…7,27 With these properties, allogeneic transplantation of MSCs are used for treatment of diseases in adult and neonates. 11,26,28 ACBMNC, as a convenient source of MSC, has never been studied in prevention or treatment of BPD in preterm. Valuable SPC mainly exits in MNC layer.…”

Section: Discussionmentioning

confidence: 99%

Autologous cord blood cell infusion in preterm neonates safely reduces respiratory support duration and potentially preterm complications

Ren

Zhang

et al. 2019

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

“…The limited regenerative potential of cardiomyocytes has made cardiac regeneration therapy by stem cell transplantation a hotspot in cardiovascular disease research [68]. The therapeutic effect of stem cell transplantation depends on the survival and transplantation ability of these cells in the target organs.…”

Section: Role Of Sfrp2 In Cardiac Regeneration Therapymentioning

confidence: 99%

Multiple Roles of sFRP2 in Cardiac Development and Cardiovascular Disease

Wu¹,

Zheng²,

Zhu³

et al. 2020

Int. J. Biol. Sci.

View full text Add to dashboard Cite

The Wnt signaling pathway plays important roles in organ development and disease processes. Secreted frizzled-related protein 2 (sFRP2), a vital molecule of Wnt signaling, can regulate cardiac development and cardiovascular disease. Recent studies have suggested that sFRP2 is not only an antagonist of the canonical Wnt signaling pathway, but also has a more complex relationship in myocardial fibrosis, angiogenesis, cardiac hypertrophy and cardiac regeneration. Here, we review the role of sFRP2 and Wnt signaling in cardiac development and cardiovascular disease.

show abstract

“…Cell therapy though has made enormous progress in the forms of haematopoietic stem cell replacement, the only form of curative therapy for some forms of leukaemias, molecularly engineered T‐cell therapy, often curing patients who would have otherwise died prematurely, and induced pluripotent stem cells …”

Section: Commentmentioning

confidence: 99%

Genomic research delivering on promises: From rejuvenation to vaccines and pharmacogenetics

2020

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and Objective There has been astounding progress made in the treatment of disease over recent years. This progress is particularly marked in cell therapy and in the personalization of therapy based on genetic insight, an approach known as genomic medicine. Our objective is to comment on the progress made in cell and genomic medicine against an historical backcloth of the search for rejuvenation. Comment In 1741, close to seven decades after Antoine van Leeuwenhoek first saw his microscopic animalcules, Abraham Trembley, a tutor in Leiden, reported on an organism that could regenerate itself. The strange organism was thought to hold the secret of life. If it does, we have yet to prise the secret out. However, the ensuing study of cell programming and induced stem cells has shed considerable light on cellular development and provided new insights on the rejuvenative capacity of organisms. Inventive scientists have provided a deeper understanding of cell replication and, from this, developed new medicines for an increasing range of diseases. Targeted therapies, oligonucleotide therapy, therapeutic monoclonal antibodies and pharmacogenetics are all new therapeutic areas originating from the improved insights. More will surely follow. What is new and conclusion Immortality is for the gods, but man's search for its elusive secrets, perhaps as old as man himself, will continue. Huge leaps have been made, and effective medicines have been developed from our improved insights into the mechanism of life. However, only the foolish will predict how far this new knowledge will lead us, and more particularly, at what speed new therapies will follow.

show abstract

Stem Cells in the Treatment of Disease

Cited by 171 publications

References 88 publications

Autologous cord blood cell infusion in preterm neonates safely reduces respiratory support duration and potentially preterm complications

Autologous cord blood cell infusion in preterm neonates safely reduces respiratory support duration and potentially preterm complications

Multiple Roles of sFRP2 in Cardiac Development and Cardiovascular Disease

Genomic research delivering on promises: From rejuvenation to vaccines and pharmacogenetics

Contact Info

Product

Resources

About